- Home
- GMAB vs EXPD Comparison
GMAB vs EXPD Comparison
Compare GMAB & EXPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- EXPD
- Stock Information
- Founded
- GMAB 1999
- EXPD 1979
- Country
- GMAB Denmark
- EXPD United States
- Employees
- GMAB N/A
- EXPD N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- EXPD Oil Refining/Marketing
- Sector
- GMAB Health Care
- EXPD Consumer Discretionary
- Exchange
- GMAB Nasdaq
- EXPD Nasdaq
- Market Cap
- GMAB 13.7B
- EXPD 15.5B
- IPO Year
- GMAB N/A
- EXPD N/A
- Fundamental
- Price
- GMAB $21.45
- EXPD $115.63
- Analyst Decision
- GMAB Buy
- EXPD Sell
- Analyst Count
- GMAB 8
- EXPD 10
- Target Price
- GMAB $37.80
- EXPD $113.78
- AVG Volume (30 Days)
- GMAB 1.6M
- EXPD 1.2M
- Earning Date
- GMAB 08-07-2025
- EXPD 08-05-2025
- Dividend Yield
- GMAB N/A
- EXPD 1.29%
- EPS Growth
- GMAB 276.80
- EXPD 27.66
- EPS
- GMAB 18.36
- EXPD 6.03
- Revenue
- GMAB $3,230,902,140.00
- EXPD $11,060,256,000.00
- Revenue This Year
- GMAB $747.74
- EXPD $0.09
- Revenue Next Year
- GMAB $14.81
- EXPD $1.60
- P/E Ratio
- GMAB $11.66
- EXPD $19.21
- Revenue Growth
- GMAB 25.43
- EXPD 24.07
- 52 Week Low
- GMAB $17.24
- EXPD $100.47
- 52 Week High
- GMAB $28.56
- EXPD $131.59
- Technical
- Relative Strength Index (RSI)
- GMAB 53.47
- EXPD 50.82
- Support Level
- GMAB $20.23
- EXPD $115.88
- Resistance Level
- GMAB $21.90
- EXPD $121.69
- Average True Range (ATR)
- GMAB 0.35
- EXPD 2.40
- MACD
- GMAB 0.06
- EXPD 0.13
- Stochastic Oscillator
- GMAB 73.52
- EXPD 38.00
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About EXPD Expeditors International of Washington Inc.
Based in the US, Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. Its offers freight consolidation and forwarding, customs brokerage, warehousing and distribution, purchase order management, vendor consolidation, and numerous other value-added logistics services. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. Expeditors derives around 35% of consolidated gross revenue from airfreight, 30% from ocean freight, and 36% from customs brokerage and other services.